Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 72162-1600

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 72162-1600). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of Duloxetine Hydrochloride showing its molecular components, including a naphthalene ring, thiophene ring, and an amine hydrochloride group.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line chart depicting the proportion of patients with relapse over time, comparing duloxetine delayed-release capsules to placebo. The x-axis shows time from randomization to relapse in days, and the y-axis shows the proportion of patients with relapse. The duloxetine group is represented by a solid line, and the placebo group by a dashed line, with the placebo group showing a higher relapse proportion over time.*

FDA Label Image

Figure 2 (Duloxetine 03)

A Kaplan-Meier curve showing the proportion of patients with relapse over time in days following randomization. The graph compares treatment with Duloxetine delayed-release capsules and placebo, with Duloxetine showing a lower relapse proportion over approximately 250 days.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph showing the percentage of patients improved plotted against the percent improvement in pain from baseline. The graph includes data lines comparing Duloxetine doses of 60 mg twice daily, 60 mg once daily, 20 mg twice daily, and a placebo group, illustrating relative patient improvement across increasing pain relief thresholds.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line plot depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares three groups labeled DUL 60mg BID, DUL 60mg QD, and Placebo, showing trends in patient improvement with different dosing regimens and placebo over a range of pain improvement percentages.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph showing percent improvement in pain from baseline on the x-axis and percentage of patients improved on the y-axis. It compares Duloxetine Delayed-Release 60 mg taken twice daily, Duloxetine 60 mg once daily, and placebo groups, illustrating differences in patient pain improvement outcomes.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph showing percent improvement in pain from baseline plotted against the percentage of fibromyalgia patients improved. The graph compares four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and a placebo group. Lines trend downward from left to right, indicating fewer patients with higher percent pain improvement.*

FDA Label Image

Figure 8 (Duloxetine 08)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline, showing two groups: Placebo and Duloxetine (DUL) 60/120 mg once daily. The x-axis represents percent improvement in pain from baseline, ranging from greater than 0 to -100, and the y-axis shows the percentage of patients improved, ranging from 0 to 100.*

FDA Label Image

Figure 9 (Duloxetine 09)

A line graph comparing the percentage of patients improved over time between a placebo group and a group receiving Duloxetine 60 mg once daily. The x-axis shows percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved, illustrating greater improvement in the Duloxetine treatment group.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). Two data series are shown: Placebo marked with crosses and DUL60/120 mg once daily marked with diamonds, illustrating patient response over varying levels of pain improvement.*

FDA Label Image

Label (Lbl721621600)

Label for Duloxetine Delayed-Release Capsules, USP, 40 mg strength, containing 30 capsules. The label states each capsule contains 44.9 mg of duloxetine hydrochloride equivalent to 40 mg duloxetine. It is relabeled by Bryant Ranch Prepack, Burbank, CA, and manufactured by Towa Pharmaceutical Europe, S.L. Storage and dispensing instructions are also shown, along with the NDC 72162-1600-3 and barcodes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.